MedTrace Logo

Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms

NCT03947411 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2019-05-15

No results posted yet for this study

Summary

This is a multicenter, randomized, open Label, add-on study.

Conditions

  • Severe Influenza

Interventions

DRUG

Oseltamivir Phosphate

Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.

DRUG

Xiyanping injection+Oseltamivir Phosphate

Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.

Sponsors & Collaborators

  • The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

    collaborator OTHER

  • Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

    collaborator OTHER

  • Beijing Luhe Hospital

    collaborator OTHER

  • Qingdao Municipal Hospital

    collaborator OTHER

  • Cangzhou People's Hospital

    collaborator OTHER

  • Jiangxi Qingfeng Pharmaceutical Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-04
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03947411 on ClinicalTrials.gov